Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608282 | 0.90 | HCAR2 (0.42) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL2608302 | 0.86 | HCAR2 (0.41) | HCAR2MAPTALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL10081655 | 0.86 | ATM (0.43) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL2608262 | 0.82 | ZDHHC20 (0.46) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL12315814 | 0.82 | HCAR2 (0.42) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL2608295 | 0.82 | TSHR (0.43) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL2608284 | 0.81 | TSHR (0.51) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL18364397 | 0.81 | HCAR2 (0.44) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL2608290 | 0.80 | HCAR2 (0.43) | HCAR2MAPTALDH1A1TSHRZDHHC20 | |
| SCHEMBL2608285 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8454857-B2 | Polymerizable liquid crystal compounds, polymerizable liquid crystal compositions, liquid crystalline polymers and optically anisotropic materials | ZEON CORPORATION (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8262931-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, polymer and film | FUJIFILM CORPORATION (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8262931-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, polymer and film | FUJIFILM CORPORATION (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8158021-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article | ZEON CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20110233464-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER AND FILM | FUJIFILM CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110233464-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER AND FILM | FUJIFILM CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110140041-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS | ZEON CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | ZEON CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110140041-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS | CCNB1, CCNT1, CCNB2 | HCAR2 4232/4885ATM 2719/4885MAPT 303/4885 |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | LEO1, ZYX, CCNT1 | HCAR2 4232/4885ATM 2814/4885MAPT 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.